Severe lupus nephritis: The predictive value of a ≥50% reduction in proteinuria at 6 months

Nephrology Dialysis Transplantation

Volumn 28, Issue 9, 2013, Pages 2313-2318

  Korbet, Stephen M ^a   Lewis, Edmund J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Proteinuria; Remission; Severe lupus nephritis

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PLASMAPHERESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEINURIA; REMISSION; SURVIVAL RATE;

PROTEINURIA; REMISSION; SEVERE LUPUS NEPHRITIS;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; PLASMAPHERESIS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS;

EID: 84884512141     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft201     Document Type: Article

References (33)

1. Appel GB, Cohen DJ, Pirani CL et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885
2. Fraenkel L, MacKenzie T, Joseph L et al. Response to treatment as a predictor of long term outcome in patients with lupus nephritis. J Rheumatol 1994; 21: 2052-2057
3. Levey AS, Lan SP, Corwin HL et al. the Lupus Nephritis Collaborative Study Group. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116: 114-123
4. Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53
5. Korbet SM, Lewis EJ, Schwartz MM et al. for the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914
6. Chan TM, Tse KC, Tang CS et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272
7. Cortes-Hernandez J, Ordi-Ros J, Labrador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296
8. Mok CC, Ying KY, Ng WL et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119: 355.e25-355.e33
9. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112
10. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
11. Korbet SM, Lewis EJ. Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria. Nephrol Dial Transplant 2012; 27: 2813-2819
12. Ioannidis JP, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264
13. Lewis EJ, Hunsicker LG, Lan SP et al. the Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1373-1379
14. Clough JD, Lewis EJ, Lachin JM, the Lupus Nephritis Collaborative Study Group. Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. In: Rock G (ed.). Progress in Clinical and Biological Research:337. New York:Wiley-Liss, 1990, pp. 301-307
15. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
16. Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Disease, Second ed. Tokyo; New York: Igaku-Shoin, 1995, 151-155
17. Schwartz MM, Lan SP, Bonsib SM et al. the Lupus Nephritis Collaborative Study Group. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13: 273-283
18. Schwartz MM, Bernstein J, Hill GS et al. the Lupus Nephritis Collaborative Study Group. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989; 36: 891-896
19. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163
20. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
21. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
22. Reich HN, Gladman DD, Urowitz MB et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int 2011; 79: 914-920
23. Dooley MA, Hogan S, Jennette C et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney International 1997; 51: 1188-1195
24. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
25. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084
26. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus 2005; 14: 25-30
27. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-629
28. Renal Disease Subcommittee of the American College of RheumatologyAd Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432
29. Gordon C, Jayne D, Pusey C et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263
30. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940
31. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year followup data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
32. Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012; 14: 202
33. Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782